CVX vs DHR: Which Is the Better Buy?
Side-by-side comparison of Chevron Corporation and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Chevron Corporation · Energy
$173.63
-3.3% upside to fair value
Grade D
VS
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
CVX trades at a lower forward P/E
(30.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CVX |
DHR |
| Current Price |
$173.63 |
$177.17 |
| Fair Value Estimate |
$167.85 |
$192.90 |
| Upside to Fair Value |
-3.3%
|
+8.9%
|
| Market Cap |
$345.8B |
$125.4B |
| Forward P/E |
30.0x
|
34.1x
|
| EV / EBITDA |
9.3x
|
20.8x
|
| Price / Sales |
1.9x
|
5.1x
|
| Price / FCF |
25.9x
|
23.7x
|
| Revenue Growth YoY |
+3.2%
|
+3.7%
|
| Gross Margin |
25.4%
|
60.7%
|
| Operating Margin |
8.4%
|
21.0%
|
| Return on Equity |
6.2%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.87%
|
4.22%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Chevron Corporation is a leading integrated oil and gas company with a strong competitive moat based on its scale, advantaged upstream resource positions, and integrated infrastructure. The company benefits from a stable and experienced leadership team, with CEO Mike Wirth having over 40 years at Chevron and a conservative capital allocation approach focused on dividends and opportunistic buyback…
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Accumulation Zones
| Metric |
CVX |
DHR |
| Zone Low |
$125.89 |
$144.68 |
| Zone High |
$142.67 |
$163.97 |
| In Buy Zone? |
No
|
No
|